MACK Merrimack Pharmaceuticals Inc.

14.52
-0.05  -0%
Previous Close 14.57
Open 14.60
Price To book 1.81
Market Cap 192825600
Shares 13,280,000
Volume 253,357
Short Ratio 24.24
Av. Daily Volume 155,286

SEC filingsSee all SEC filings

  1. 8-K - Current report 171088282
  2. 8-K - Current report 171070211
  3. 8-K - Current report 171027883
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018316
  5. 8-K - Current report 171016467

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation due 2017.
MM-121
HER2 negative metastatic breast cancer
Phase 2 completion of enrollment announced June 19, 2017. Data due 1H 2018.
MM-141 - CARRIE
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
MM-302 HERMIONE
Cancer - HER2-positive locally advanced or metastatic breast cancer
Approved October 22, 2015.
ONIVYDE
Cancer - second line pancreatic
Phase 2 initiated mid Feb 2015. Data due 2H 2018.
MM-121
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
ONIVYDE
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
ONIVYDE
Cancer - front line pancreatic

Latest News

  1. Today's Research Reports on Trending Tickers: American Superconductor and Merrimack Pharmaceuticals
  2. Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers
  3. Merrimack Announces Date of One-for-Ten Reverse Stock Split
  4. Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer
  5. Edited Transcript of MACK earnings conference call or presentation 9-Aug-17 12:30pm GMT
  6. Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls
  7. Merrimack misses 2Q profit forecasts
  8. Merrimack's (MACK) Reports Wider-than-Expected Q2 Loss
  9. Merrimack Reports Second Quarter 2017 Financial Results
  10. Investor Network: Merrimack Pharmaceuticals, Inc. to Host Earnings Call
  11. Merrimack Announces Timing of Second Quarter 2017 Investor Conference Call
  12. ETFs with exposure to Merrimack Pharmaceuticals, Inc. : August 1, 2017
  13. What's in the Cards for Merrimack (MACK) in Q2 Earnings?
  14. Merrimack Appoints Thomas Needham as Chief Business Officer
  15. Edited Transcript of MACK earnings conference call or presentation 1-Mar-17 1:30pm GMT
  16. Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Moleculin Biotech and Merrimack Pharmaceuticals
  17. These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop?
  18. Merrimack Completes Enrollment in Phase II Study for MM-141
  19. Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018
  20. Why Is Merrimack (MACK) Down 57.6% Since the Last Earnings Report?

SEC Filings

  1. 8-K - Current report 171088282
  2. 8-K - Current report 171070211
  3. 8-K - Current report 171027883
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018316
  5. 8-K - Current report 171016467
  6. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17965649
  7. 8-K - Current report 17965638
  8. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17929137
  9. DEF 14A - Other definitive proxy statements 17929135
  10. 8-K - Current report 17916618